June 2026

IP KNOWLEDGE EXTRACT

EVOLVING STANDARDS FOR PATENT DISCLOSURE IN PHARMACEUTICAL AND BIOTECHNOLOGY INVENTIONS IN VIETNAM

By Uyen Ngo, Nguyen Hoa Binh, et al.

What's New



Overview

Vietnam's patent system has undergone significant development in recent years, particularly in the examination of pharmaceutical and biotechnology inventions. While the fundamental requirement that an invention must be sufficiently disclosed has long been established under the Law on Intellectual Property, practical application of this requirement has become increasingly sophisticated as examiners confront complex inventions involving chemical compounds, biological materials, and therapeutic technologies.

Recent amendments to examination practices demonstrate the Intellectual Property Office of Vietnam's intention to adopt a more structured approach to evaluating patent specifications in life science inventions. Applicants are therefore required not only to describe their inventions in a technically complete manner but also to provide sufficient evidence that the claimed subject matter can be reproduced and achieves the promised technical effects.

As pharmaceutical and biotechnology applications continue to increase, understanding the evolving standards of disclosure has become essential for both patent applicants and practitioners.

The Increasing Importance of Sufficient Disclosure

The requirement of sufficient disclosure serves as one of the fundamental principles of patent law. In exchange for the exclusive rights granted by a patent, the applicant must provide the public with enough information to enable a person skilled in the art to carry out the invention.

For conventional mechanical or electrical inventions, this requirement is often satisfied through structural descriptions, drawings, and working examples. However, pharmaceutical and biotechnology inventions present additional challenges because their technical effects frequently depend on biological activity, therapeutic efficacy, or complex molecular interactions.

A mere statement that a compound possesses a certain medical effect may no longer be considered adequate. Patent examiners increasingly expect the specification to contain supporting information demonstrating why the claimed invention works and how the asserted effects can be achieved.

In practice, this means that applicants must carefully consider the amount of experimental information included in the original application. Insufficient disclosure may lead to objections relating to enablement, clarity, or even industrial applicability. Once the application has been filed, correcting these deficiencies may become difficult because amendments are restricted by the prohibition against introducing new matter.

The growing emphasis on disclosure requirements therefore shifts much of the patent strategy to the drafting stage. Applicants must ensure that the specification contains enough information to support the full breadth of the claims while avoiding unnecessary limitations.

Experimental Evidence and Technical Effects

One of the most significant developments in pharmaceutical patent examination is the increased focus on experimental evidence. Modern pharmaceutical inventions often rely on demonstrating biological activities, therapeutic properties, or pharmacological effects that distinguish the invention from existing technologies.

Patent specifications are therefore expected to explain not only the composition of a pharmaceutical product but also the evidence supporting its medical usefulness. Experimental results may involve clinical studies, animal experiments, cellular assays, or in vitro testing systems.

Quantitative information plays an important role in this assessment. Numerical data, comparative examples, dosage information, and measurable results can help establish the relationship between the claimed invention and its asserted therapeutic effect.

Examiners may question applications that merely speculate about medical uses without presenting supporting evidence. Similarly, where test results are disclosed without clearly identifying the tested compound or composition, the reliability of the disclosed effect may become uncertain.

The relationship between experimental evidence and inventive step is also becoming increasingly important. Data demonstrating unexpected advantages or superior efficacy may contribute to establishing inventiveness over prior art. Consequently, applicants frequently rely on experimental evidence not only to satisfy disclosure requirements but also to support patentability.

For biotechnology inventions, experimental evidence may involve expression studies, binding assays, biological activity measurements, or genetic analyses. Such data help demonstrate that the claimed biological material performs the function described in the application.

The inclusion of comprehensive experimental information at the filing stage therefore provides a stronger foundation for subsequent examination.

Challenges in Claiming Biological Materials and Broad Chemical Inventions

Biotechnology inventions often involve subject matter that cannot be easily described through conventional structural definitions. Genes, proteins, antibodies, and other biological materials may possess complex properties that are difficult to characterize completely.

Modern examination practice generally favors structural definitions whenever possible. Amino acid sequences, nucleotide sequences, and molecular structures provide objective information that enables a skilled person to identify the claimed subject matter.



Functional definitions based solely on biological properties may raise concerns regarding clarity and enablement. For example, a claim directed merely to a protein possessing a particular biological activity may encompass numerous undisclosed variants whose properties remain uncertain.

Similarly, inventions involving broad chemical genera, including Markush claims, present their own difficulties. A claim may cover hundreds or thousands of possible compounds while only a limited number of examples are provided in the specification.

Examiners increasingly assess whether the disclosed examples adequately represent the entire claimed scope. If only a small portion of the claimed compounds has been synthesized or tested, questions may arise regarding whether the asserted effects extend across all embodiments.

Applicants may therefore need to demonstrate that the disclosed examples are representative of the broader class of compounds. This issue becomes particularly important when biological activity or therapeutic efficacy forms the basis of the invention.

Sequence listings also remain an important aspect of biotechnology applications. Standardized presentation formats improve consistency and facilitate examination. However, practical challenges may arise during filing and publication procedures, particularly where sequence information must be submitted in multiple formats or reproduced for administrative purposes.

As biotechnology innovations become increasingly complex, drafting strategies must evolve to ensure that claims remain adequately supported by the description.

The Role of Post-Filing Evidence and Amendments

Patent applicants frequently seek to submit additional experimental data after filing in order to respond to examination objections or strengthen arguments regarding inventive step. The treatment of such evidence represents one of the most debated issues in pharmaceutical patent practice worldwide.

The general principle is that post-filing evidence cannot replace information that should have been disclosed in the original application. The specification itself must already provide sufficient disclosure of the invention and its technical effects.

Additional data may nevertheless be useful to confirm, clarify, or reinforce effects that were already described. Comparative studies generated after filing may help demonstrate the advantages of the claimed invention over prior art references.

The acceptability of post-filing evidence often depends on whether the technical effect relied upon was already apparent from the original disclosure. If the application initially contains no indication of a particular advantage, later experimental results may be viewed as introducing new technical information.



Amendments are similarly subject to strict limitations. Changes that introduce new technical content or alter the nature of the disclosed invention are generally prohibited. This restriction emphasizes the importance of preparing comprehensive specifications before filing.

Disclaimers also remain a challenging area. Excluding specific embodiments from a claim may be permissible under certain circumstances, particularly where the excluded subject matter is unpatentable or contrary to public policy. However, the scope and acceptability of disclaimers often depend on the factual circumstances of each case.

Applicants should therefore exercise caution when relying on post-filing evidence or amendment strategies to overcome deficiencies in the original application.

Conclusion

The examination of pharmaceutical and biotechnology patents in Vietnam is becoming increasingly detailed and technically demanding. Sufficient disclosure is no longer assessed solely by whether the invention can theoretically be reproduced. Examiners increasingly evaluate whether the specification adequately demonstrates the technical contribution, biological activity, and practical implementation of the claimed invention.

Experimental evidence, representative examples, structural definitions, and adequate support for broad claims all play important roles in modern patent examination. The growing emphasis on these factors reflects international trends and encourages higher-quality patent drafting.

For applicants and practitioners, the most effective approach is to prepare comprehensive specifications from the outset, ensuring that technical effects, experimental methods, and supporting data are clearly disclosed. As examination practice continues to evolve, careful drafting and strategic planning will remain essential to securing effective patent protection for pharmaceutical and biotechnology inventions in Vietnam.

Contact

DAITIN & ASSOCIATES
Lawyers and Consultants

Please contact Daitin & Associates if you require any further information or guidance in the procedures of acquiring, protecting intellectual property rights in Vietnam | Cambodia | Laos | Myanmar | Thailand | Philippines | Brunei | Indonesia.

info@daitin.com.vn | www.daitin.com.vn